Journal Scans
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Semuloparin Reduces Thromboemobolism in Patients on Chemotherapy
G Agnelli, DJ George, AK Kakkar, W Fisher, MR Lassen, P Mismetti, P Mouret, U Chaudhari, F Lawson, AGG Turpie
Yes
20120116
2012 Feb 16
N Engl J Med
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
N Engl J Med. 2012 Feb 16;366(7):601-609, G Agnelli, DJ George, AK Kakkar, W Fisher, MR Lassen, P Mismetti, P Mouret, U Chaudhari, F Lawson, AGG Turpie
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Chemotherapy is a risk factor for venous thromboembolism, but there are limited data regarding the benefit of antithrombotic prophylaxis in ambulatory cancer patients receiving chemotherapy. Semuloparin is a hemisynthetic, ultra–low molecular weight heparin with high anti-Xa activity and minimal anti-IIa activity. The SAVE-ONCO Study Group assessed the efficacy and safety of semuloparin as prophylaxis against venous thromboembolism in patients receiving chemotherapy for solid tumors.SAVE-ONCO, sponsored...
